Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (53,060)	$ (51,663)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation, amortization and accretion	1,459	1,787
Stock-based compensation expense	4,152	2,516
Loss on extinguishment of debt, net	53	830
Loss on sale, abandonment/disposal or impairment of property and equipment		87
(Gain) Loss on foreign currency translation	(2,379)	8,392
Interest on note payable to related party	2,219	1,435
Change in fair value of warrant liability		(6,776)
Write-off of inventory	779	1,460
Other, net	106	3
Changes in operating assets and liabilities:
Accounts receivable, net	(170)	(1,010)
Receivable from Sanofi		30,557
Inventory	(1,798)	(2,301)
Deferred costs from commercial product sales		(191)
Prepaid expenses and other current assets	440	1,800
Other assets	79	125
Accounts payable	2,253	3,357
Accrued expenses and other current liabilities	818	(483)
Deferred revenue		(827)
Deferred payments from collaboration	2,049	(125)
Recognized loss on purchase commitments	(5,800)	(500)
Net cash used in operating activities	(48,800)	(11,527)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net proceeds from sale of asset held for sale		16,651
Proceeds from sale of property and equipment		24
Net cash provided by investing activities		16,675
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from direct placement of common stock	28,000
Issuance cost associated with direct placement	(1,610)
Principal payments on facility financing obligation		(4,000)
Borrowings on note payable to related party		19,429
Payment of employment taxes related to vested restricted stock units	(184)	(88)
Proceeds from issuance of common stock pursuant to at-the-market issuance	634
Issuance cost of at-the-market transactions	(25)
Proceeds from executive stock purchase plan	335
Net cash provided by financing activities	27,150	15,341
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(21,650)	20,489
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	48,355	22,895
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	26,705	43,384
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized	1,860	4,141
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of note obligations through common stock issuance, net of issuance costs	20,405	11,000
Payment of note payable to related party through common stock issuance	8,160
Capitalization of interest on note payable to related party		$ 10,716
Accrued but unpaid debt issuance costs	$ 156